THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 123 filers reported holding THERAVANCE BIOPHARMA INC in Q4 2022. The put-call ratio across all filers is 0.21 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $493,044 | -5.5% | 58,142 | 0.0% | 0.06% | -7.6% |
Q1 2024 | $521,534 | -20.2% | 58,142 | 0.0% | 0.07% | -26.7% |
Q4 2023 | $653,516 | +30.2% | 58,142 | 0.0% | 0.09% | +18.4% |
Q3 2023 | $501,765 | -16.6% | 58,142 | 0.0% | 0.08% | -12.6% |
Q2 2023 | $601,770 | -4.6% | 58,142 | 0.0% | 0.09% | -10.3% |
Q1 2023 | $630,841 | -3.3% | 58,142 | 0.0% | 0.10% | -8.5% |
Q4 2022 | $652,353 | +10.6% | 58,142 | 0.0% | 0.11% | +5.0% |
Q3 2022 | $590,000 | +12.0% | 58,142 | 0.0% | 0.10% | +17.4% |
Q2 2022 | $527,000 | -5.0% | 58,142 | 0.0% | 0.09% | +14.7% |
Q1 2022 | $555,000 | -13.6% | 58,142 | 0.0% | 0.08% | -7.4% |
Q4 2021 | $642,000 | +49.0% | 58,142 | 0.0% | 0.08% | +39.7% |
Q3 2021 | $431,000 | -48.9% | 58,142 | 0.0% | 0.06% | -48.2% |
Q2 2021 | $844,000 | -28.9% | 58,142 | 0.0% | 0.11% | -33.7% |
Q1 2021 | $1,187,000 | +75.3% | 58,142 | +52.4% | 0.17% | +62.5% |
Q4 2020 | $677,000 | +20.0% | 38,142 | 0.0% | 0.10% | +3.0% |
Q3 2020 | $564,000 | -29.6% | 38,142 | 0.0% | 0.10% | -33.1% |
Q2 2020 | $801,000 | -9.1% | 38,142 | 0.0% | 0.15% | -24.9% |
Q1 2020 | $881,000 | -10.8% | 38,142 | 0.0% | 0.20% | +19.6% |
Q4 2019 | $988,000 | +33.0% | 38,142 | 0.0% | 0.17% | +23.5% |
Q3 2019 | $743,000 | +46.3% | 38,142 | +22.5% | 0.14% | +49.5% |
Q2 2019 | $508,000 | -28.0% | 31,142 | 0.0% | 0.09% | -28.9% |
Q1 2019 | $706,000 | -5.4% | 31,142 | +6.9% | 0.13% | -17.4% |
Q4 2018 | $746,000 | -33.1% | 29,142 | -14.6% | 0.16% | -18.4% |
Q3 2018 | $1,115,000 | +44.1% | 34,142 | 0.0% | 0.19% | +37.7% |
Q2 2018 | $774,000 | -6.5% | 34,142 | 0.0% | 0.14% | -6.8% |
Q1 2018 | $828,000 | -13.0% | 34,142 | 0.0% | 0.15% | -10.3% |
Q4 2017 | $952,000 | +15.1% | 34,142 | +41.4% | 0.16% | +10.0% |
Q3 2017 | $827,000 | -57.9% | 24,142 | -51.0% | 0.15% | -59.6% |
Q2 2017 | $1,964,000 | +8.2% | 49,284 | 0.0% | 0.37% | +7.5% |
Q1 2017 | $1,815,000 | +15.5% | 49,284 | 0.0% | 0.34% | +10.6% |
Q4 2016 | $1,571,000 | -12.0% | 49,284 | 0.0% | 0.31% | -15.7% |
Q3 2016 | $1,786,000 | +59.7% | 49,284 | 0.0% | 0.37% | +55.5% |
Q2 2016 | $1,118,000 | +8.9% | 49,284 | 0.0% | 0.24% | +9.2% |
Q1 2016 | $1,027,000 | +27.1% | 49,284 | 0.0% | 0.22% | +31.3% |
Q4 2015 | $808,000 | +49.4% | 49,284 | 0.0% | 0.17% | +41.9% |
Q3 2015 | $541,000 | +190.9% | 49,284 | +245.0% | 0.12% | +225.0% |
Q2 2015 | $186,000 | -25.0% | 14,284 | 0.0% | 0.04% | -25.0% |
Q1 2015 | $248,000 | +15.9% | 14,284 | 0.0% | 0.05% | +14.3% |
Q4 2014 | $214,000 | -35.2% | 14,284 | 0.0% | 0.04% | -37.3% |
Q3 2014 | $330,000 | -27.6% | 14,284 | 0.0% | 0.07% | -25.6% |
Q2 2014 | $456,000 | – | 14,284 | – | 0.09% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Chescapmanager LLC | 1,157,718 | $17,117,000 | 2.77% |
Baupost Group | 8,735,168 | $129,149,000 | 1.40% |
Orbimed Advisors | 6,219,110 | $91,950,000 | 1.16% |
Rubric Capital Management LP | 550,747 | $8,143,000 | 0.76% |
Cormorant Asset Management, LP | 650,072 | $9,611,000 | 0.37% |
Rock Springs Capital Management LP | 824,018 | $12,183,000 | 0.31% |
Virtus ETF Advisers LLC | 23,148 | $342,000 | 0.18% |
Tekla Capital Management LLC | 298,470 | $4,413,000 | 0.16% |
PEREGRINE CAPITAL MANAGEMENT LLC | 412,594 | $6,100,000 | 0.16% |
NJ State Employees Deferred Compensation Plan | 38,142 | $564,000 | 0.10% |